Changes in T-cell receptor repertoire in aplastic anemia and effects of Shengxue Mixture.
- Author:
Yong-ming ZHOU
1
;
Xue-li WEI
;
Jia-hui LU
Author Information
- Publication Type:Clinical Trial
- MeSH: Adolescent; Adult; Aged; Anemia, Aplastic; drug therapy; genetics; immunology; Drugs, Chinese Herbal; pharmacology; therapeutic use; Female; Gene Expression; drug effects; Gene Rearrangement, beta-Chain T-Cell Antigen Receptor; Humans; Male; Middle Aged; Phytotherapy; Receptors, Antigen, T-Cell, alpha-beta; biosynthesis; genetics; Reverse Transcriptase Polymerase Chain Reaction
- From: Chinese Journal of Integrated Traditional and Western Medicine 2006;26(11):973-977
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the immune pathogenesis of aplastic anemia (AA) and the therapeutic effects of Shengxue Mixture (SM) through the gene expressions of subfamilies of T-cell receptor variable region beta (TCR Vbeta) using immunologic and molecular biologic technology.
METHODSGene expressions of TCR Vbeta sub-families in peripheral blood mononuclear cells from 20 AA patients were detected before and after treatment with SM using RT-PCR and gene scanning method.
RESULTSTCR Vbeta gene repertoire of the 24 subfamily genes deviated in AA patients, and the oligoclonal gene expressions increased obviously compared with those in healthy people (P < 0.01), including Vbeta2, 5, 6, 15, 16, 22, and 23 were found in 30%-50% AA patients, and Vbeta8, 21 were in more than 50% patients. These oligoclonal genes reduced significantly after treatment with SM compared with those before treatment (P < 0.05).
CONCLUSIONMultiple TCR Vbeta subfamilies of clonal proliferation participate in the pathogenesis of AA. SM can rectify the deviation of TCR Vbeta gene repertoire, reduce the abnormal clonal proliferation of T cells, thus to alleviate the immune injury to hematopoietic tissue, and thus to benefit the recovery of hematopoiesis of bone marrow.
